Compare Ascendis Pharma A/S (ASND) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Zoom Video Communications, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Zoom Video Communications, Inc. trades at $90.2 (market cap $26.32B). The key difference: Zoom Video Communications, Inc. is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | ZM | |
|---|---|---|
Market Cap | $17.74B | $26.32B |
Sector | Health | Technology |
52-Week High | $277.18 | $111.88 |
52-Week Low | $163.32 | $69.77 |
Enterprise Value | $18.11B | $18.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Zoom Communications (ZM) trades at $89.76, showing modest daily movement with a slight 0.13% decline. The stock maintains bullish technical signals with strong moving average support and trades near pivot point resistance at $91. Fundamentally, Zoom demonstrates robust profitability with 77.4% gross margins and 42% net income margins, while recent Q1 2026 earnings beat expectations. The company continues expanding AI capabilities through acquisitions like Common Room and new Virtual Agent offerings.
Zoom presents a compelling value opportunity trading below analyst consensus targets with 32% upside potential. Strong cash generation, AI integration progress, and strategic Anthropic investment provide catalysts, though competitive pressures from Microsoft and Google remain key risks. Wall Street maintains cautious optimism with mixed analyst ratings reflecting growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
